𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Zoledronic acid (ZOMETA): a significant improvement in the treatment of Bone metastases

✍ Scribed by Zsuzsanna Nagy

Publisher
Springer Netherlands
Year
2005
Tongue
English
Weight
52 KB
Volume
11
Category
Article
ISSN
1219-4956

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Normalization of bone markers is associa
Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid
✍ Allan Lipton; Richard Cook; Fred Saad; Pierre Major; Patrick Garnero; Evangelos πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 219 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. For patients with bone metastases, high N‐telopeptide of type I collagen (NTX) levels correlate with increased risks of skeletal‐related events and death. However, the relation between NTX decreases and clinical benefits is unclear. ## METHODS. Correlations between NTX

Zoledronic acid is superior to pamidrona
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion
✍ Lee S. Rosen; David H. Gordon; William Dugan Jr.; Pierre Major; Peter D. Eisenbe πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 131 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Treatment with zoledronic acid (Zol) was compared with a dose of 90 mg of pamidronate (Pam) in breast carcinoma (BC) patients with at least 1 osteolytic lesion based on data from a Phase III, randomized trial. ## METHODS Overall, 1130 patients with breast carcinoma who